300725.SZ
药石科技
SZSE · Healthcare · M 科研服务 · CN
CNY 48.31
−6.12%Year over year
Reported trailing growth
- Revenue
- +14.8%
- EBITDA
- —
- EBIT
- -4.7%
- EPS
- -9.9%
- Free cash flow
- -31.1%
- Operating cash flow
- -5.7%
Forward estimates
Based on analyst estimates
- Revenue
- -7.7%
- EBITDA
- +101.2%
- EPS
- +125.3%
Three-year CAGR
- Revenue
- +7.4%
- EBITDA
- -3.3%
- EBIT
- -10.8%
- Net income
- -16.4%
- EPS
- -17.7%
- Free cash flow
- +185.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026